Inclusion body myositis

Current Opinion in Neurology

Volumn 12, Issue 5, 1999, Pages 527-533

  Oldfors, Anders ^a   Lindberg, Christopher ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME C OXIDASE; IMMUNOSUPPRESSIVE AGENT; PROTEIN;

AGING; CELL VACUOLE; DYSPHAGIA; HUMAN; INCLUSION BODY MYOSITIS; INFLAMMATION; MUSCLE ATROPHY; MUSCLE WEAKNESS; PATHOGENESIS; REVIEW; TREATMENT FAILURE;

HUMANS; IMMUNOTHERAPY; MITOCHONDRIA, MUSCLE; MUSCLE WEAKNESS; MYOSITIS, INCLUSION BODY; VACUOLES;

EID: 0033381705     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199910000-00006     Document Type: Review

References (93)

1. 1 Chou SM. Myxovirus-like structures and accompanying nuclear changes in chronic polymyositis. Arch Pathol 1968; 86:649-658.
2. 2 Yunis EJ, Samaha FJ. Inclusion body myositis. Lab Invest 1971; 25:240-248.
3. 3 Askanas V, Serratrice G, Engel WK (editors). Inclusion-body myositis and myopathies. Cambridge, UK: Cambridge University Press; 1998. This book summarizes most of the recent advances and current knowledge of sporadic IBM, and includes new information.
4. 4 Semino-Mora C, Dalakas MC. Rimmed vacuoles with beta-amyloid and ubiquitinated filamentous deposits in the muscles of patients with long-standing denervation (postpoliomyelitis muscular atrophy): similarities with inclusion body myositis. Hum Pathol 1998; 29:1128-1133. This report gives one further example of the unspecificity of the IBM inclusions (i.e. they can be observed at low frequency in a variety of muscle diseases).
5. 5 Sekul EA, Chow C, Dalakas MC. Magnetic resonance imaging of the forearm as a diagnostic aid in patients with sporadic inclusion body myositis. Neurology 1997; 48:863-866.
6. 6 Brannagan TH, Hays AP, Lange DJ, Trojaborg W. The role of quantitative electromyography in inclusion body myositis. J Neurol Neurosurg Psychiatry 1997; 63:776-779.
7. 7 Barkhaus PE, Periquet MI, Nandedkar SD. Quantitative electrophysiologic studies in sporadic inclusion body myositis. Muscle Nerve 1999; 22:480-487. This extensive and thorough study shows myopathic motor unit potential pattern.
8. 8 Koffman BM, Rugiero M, Dalakas MC. Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle Nerve 1998; 21:115-117. The reported high frequency of autoantibodies or other autoimmune diseases supports the concept of altered immune function in sporadic IBM.
9. 9 Lindberg C, Persson L, Björkander J, Oldfors A. Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases. Acta Neurol Scand 1994; 89:123-131.
10. 10 Lotz BP, Engel AG, Nishino H, Stevens JC, Litchy WJ. Inclusion body myositis. Observations in 40 patients. Brain 1989; 112:727-747.
11. 11 Hengstman GJ, van Engelen BG, Badrising UA, van den Hoogen FH, van Venrooij WJ. Presence of the anti-Jo-1 autoantibody excludes inclusion body myositis [letter]. Ann Neurol 1998; 44:423.
12. 12 Houser SM, Calabrese LH, Strome M. Dysphagia in patients with inclusion body myositis. Laryngoscope 1998; 108:1001-1005. Dysphagia is an under recognized and disabling consequence of sporadic IBM that can be treated.
13. 13 Lindberg C, Oldfors A. Prognostic factors in sporadic inclusion body myositis [abstract]. Muscle Nerve 1998; (Suppl 7):S130. This paper presents long-term prognosis in sporadic IBM based on up to 10 years isometric muscle strength measurements.
14. 14 Griggs RC, Rose MR. Evaluation of treatment of sporadic inclusion-body myositis. In: Inclusion-body myositis and myopathies. Askanas V, Serratrice G, Engel WK (editors). Cambridge, UK: Cambridge University Press; 1998. pp. 331-350. This is an extensive review of rationale and experience of treatment of sporadic IBM.
15. 15 Mastaglia FL, Phillips BA, Zilko P. Treatment of inflammatory myopathies. Muscle Nerve 1997; 20:651-664.
16. 16 Dalakas MC. Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Neurology 1998; 51 (Suppl 5):S37-S45. This is an extensive and informative review of IVIG treatment, including not otherwise published data.
17. 17 Engel WK, Askanas V. Treatment of inclusion-body myositis and hereditary inclusion-body myopathy with reference to pathogenic mechanisms: personal experience. In: Inclusion-body myositis and myopathies. Askanas V, Serratrice G, Engel WK (editors). Cambridge, UK: Cambridge University Press; 1998. pp. 351-382.
18. 18 Mastaglia FL, Phillips BA, Zilko PJ. Immunoglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry 1998; 65:107-110. This is an open, nonrandomized study in five sporadic IBM patients showing no benefit of IVIG in four and some increase in muscle strength in one patient.
19. 19 Johannes S, Schubert M, Heidenreich F, Walter GF, Dengler R. Inclusion body myositis: immune globulins improve muscle strength, but not abnormal postures. J Neurol 1998; 245:816-818.
20. 20 Soueidan SA, Dalakas MC. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 1993; 43:876-879.
21. 21 Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997; 48:712-716.
22. 22 Pongratz D, Lochmüller H, Toepfer M, Schlotter B, Schröder M, Müller-Felber W, et al. High dose intravenous immunoglobulin (IVIG) in the treatment of inclusion body myositis: a double-blind, placebo-controlled study [Abstract). Muscle Nerve 1998; (Suppl 7):S132.
23. 23 Felice KJ, Relva GM, Conway SR. Further observations on forearm flexor weakness in inclusion body myositis. Muscle Nerve 1998; 21:659-661. Sporadic IBM patients are stronger in the dominant hand-'training' effect?
24. 24 Spector SA, Lemmer JT, Koffman BM, Fleisher TA, Feuerstein IM, Hurley BF, Dalakas MC. Safety and efficacy of strength training in patients with sporadic inclusion body myositis. Muscle Nerve 1997; 20:1242-1248.
25. 25 Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, Rowland LP. Inclusion body myositis and myopathies. Ann Neurol 1995; 38:705-713.
26. 26 Pruitt JN, Showalter CJ, Engel AG. Sporadic inclusion body myositis: counts of different types of abnormal fibers. Ann Neurol 1996; 39:139-143.
27. 27 Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984; 16:209-215.
28. 28 De Bleecker JL, Engel AG. Immunocytochemical study of CD45 T cell isoforms in inflammatory myopathies. Am J Pathol 1995; 146:1178-1187.
29. 29 Fyhr IM, Moslemi AR, Tarkowski A, Lindberg C, Oldfors A. Limited T-cell receptor V gene usage in inclusion body myositis. Scand J Immunol 1996; 43:109-114.
30. 30 Fyhr IM, Moslemi AR, Mosavi AA, Lindberg C, Tarkowski A, Oldfors A. Oligoclonal expansion of muscle infiltrating T cells in inclusion body myositis. J Neuroimmunol 1997; 79:185-189.
31. 31 Fyhr IM, Moslemi AR, Lindberg C, Oldfors A. T cell receptor beta-chain repertoire in inclusion body myositis. J Neuroimmunol 1998; 91:129-134. Spectratyping of T-cell receptor CDR3 region shows clonal expensions of T cells in muscle in sporadic IBM.
32. 32 Lindberg C, Oldfors A, Tarkowski A. Restricted use of T cell receptor V genes in endomysial infiltrates of patients with inflammatory myopathies. Eur J Immunol 1994; 24:2659-2663.
33. 33 O'Hanlon TP, Dalakas MC, Plotz PH, Miller FW. The αβ T-cell receptor repertoire in inclusion body myositis: diverse patterns of gene expression by muscle-infiltrating lymphocytes. J Autoimmun 1994; 7:321-333.
34. 34 Bender A, Behrens L, Engel AG, Hohlfeld R. T-cell heterogeneity in muscle lesions of inclusion body myositis. J Neuroimmunol 1998; 84:86-91. This elegant study shows that autoaggressive T cells are clonally restricted in sporadic IBM, whereas interstial T cells are clonally diverse.
35. 35 Bemasconi P, Confalonieri P, Andreetta F, Baggi F, Cornelio F, Mantegazza R. The expression of co-stimulatory and accessory molecules on cultured human muscle cells is not dependent on stimulus by pro-inflammatory cytokines: relevance for the pathogenesis of inflammatory myopathy. J Neuroimmunol 1998; 85:52-58.
36. 36 Behrens L, Kerschensteiner M, Misgeld T, Goebels N, Wekerle H, Hohlfeld R. Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions. J Immunol 1998; 161:5943-5951. This paper describes the presence of a functional costimulatory molecule, which is upregulated and expressed by muscle fibres in inflamatory myopathies. This discovery is important for understanding muscle immunobiology.
37. 37 Lundberg IE, Nyberg P. New developments in the role of cytokines and chemokines in inflammatory myopathies. Curr Opin Rheumatol 1998; 10:521-529. An interesting discussion on possible roles of cytokines in pathogenesis of sporadic IBM and other inflammatory myopathies is presented.
38. 38 Lundberg I, Ulfgren AK, Nyberg P, Andersson U, Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997; 40:865-874.
39. 39 Smyth MJ, Trapani JA. Granzymes: exogenous proteinases that induce target cell apoptosis. Immunol Today 1995; 16:202-206.
40. 40 Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994; 370:650-652.
41. 41 Orimo S, Koga R, Goto K, Nakamura K, Arai M, Tamaki M, et al. Immunohistochemical analysis of perforin and granzyme a in inflammatory myopathies. Neuromuscular Disord 1994; 4:219-226.
42. 42 Goebels N, Michaelis D, Engelhardt M, Huber S, Bener A, Pongratz D, et al. Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest 1996; 97:2905-2910.
43. 43 Behrens L, Bender A, Johnson MA, Hohlfeld R. Cytotoxic mechanisms in inflammatory myopathies. Co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells. Brain 1997; 120:929-938.
44. 44 Fyhr IM, Oldfors A. Upregulation of Fas/Fas ligand in inclusion body myositis. Ann Neurol 1998; 43:127-130. Upregulation of Fas on muscle fibres and of Fas ligand on muscle infiltrating T cells provides a basis for the Fas-Fas ligand system to be active in sporadic IBM.
45. 45 Schneider C, Gold R, Dalakas MC, Schmied M, Lassmann H, Toyka KV, Hartung HP. MHC class I-mediated cytotoxicity does not induce apoptosis in muscle fibers nor in inflammatory T cells: studies in patients with polymyositis, dermatomyositis, and inclusion body myositis. J Neuropathol Exp Neurol 1996; 55:1205-1209.
46. 46 Hutchinson DO. Inclusion body myositis: abnormal protein accumulation does not trigger apoptosis. Neurology 1998; 51:1742-1745. Apoptosis as revealed by TUNEL staining does not appear to be of significance for muscle fibre death in sporadic IBM.
47. 47 Askanas V, Engel WK, Bilak M, Alvarez RB, Selkoe DJ. Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau. Am J Pathol 1994; 144:177-187.
48. 48 Askanas V, Engel WK. Sporadic inclusion-body myositis and its similarities to Alzheimer disease brain. Recent approaches to diagnosis and pathogenesis, and relation to aging. Scand J Rheumatol 1998; 27:389-405. This paper presents an interesting review and extensive discussion on possible pathogenesis of sporadic IBM.
49. 49 Askanas V, Engel WK, Yang CC, Alvarez RB, Lee VM, Wisniewski T. Light and electron microscopic immunolocalization of presenilin 1 in abnormal muscle fibers of patients with sporadic inclusion-body myositis and autosomal-recessive inclusion-body myopathy. Am J Pathol 1998; 152:889-895. Presenilin 1 has been added to the list of proteins that are accumulated both in Alzheimer's disease brain and IBM muscle.
50. 50 Askanas V, Alvarez RB, Engel WK. Beta-amyloid precursor epitopes in muscle fibers of inclusion body myositis. Ann Neurol 1993; 34:551-560.
51. 51 Askanas V, McFerrin J, Alvarez RB, Baque S, Engel WK. Beta APP gene transfer into cultured human muscle induces inclusion-body myositis aspects. NeuroReport 1997; 8:2155-2158.
52. 52 Jin LW, Hearn MG, Ogburn CE, Dang N, Nochlin D, Ladiges WC, Martin GM. Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-secretase site mutation develop a myopathy similar to human inclusion body myositis. Am J Pathol 1998; 153:1679-1686. This study provides important information about the possible role of β-APP in IBM.
53. 53 Fukuchi K, Pham D, Hart M, Li L, Lindsey JR. Amyloid-beta deposition in skeletal muscle of transgenic mice: possible model of inclusion body myopathy. Am J Pathol 1998; 153:1687-1693. Important information is provided about the effects of overexpression of β-APP fragments in muscle.
54. 54 Yang CC, Askanas V, Engel WK, Alvarez RB. Immunolocalization of transcription factor NF-kappaB in inclusion-body myositis muscle and at normal human neuromuscular junctions. Neurosci Lett 1998; 254:77-80. Interesting observation of upregulation of a transcription factor in vacuolated IBM muscle fibres.
55. 55 Oyama F, Murakami N, Ihara Y. Chloroquine myopathy suggests that tau is degraded in lysosomes: implication for the formation of paired helical filaments in Alzheimer's disease. Neurosci Res 1998; 31:1-8.
56. 56 Askanas V, Engel WK, Alvarez RB. Fourteen newly recognized proteins at the human neuromuscular junctions and their nonjunctional accumulation in inclusion-body myositis. Ann N Y Acad Sci 1998; 841:28-56.
57. 57 Carpenter S, Karpati G, Eisen A. A morphologic study in polymyositis: clues to pathogenesis of different types. In: Recent advances in myology. Bradley W (editor). Amsterdam: Excerpta Medica; 1975. pp. 374-379.
58. 58 Rifai Z, Welle S, Kamp C, Thornton CA. Ragged red fibers in normal aging and inflammatory myopathy. Ann Neurol 1995; 37:24-29.
59. 59 Molnar M, Schröder JM. Pleomorphic mitochondrial and different filamentous inclusions in inflammatory myopathies associated with mtDNA deletions. Acta Neuropathol (Berl) 1998; 96:41-51.
60. 60 Horvath R, Fu K, Johns T, Genge A, Karpati G, Shoubridge EA. Characterization of the mitochondrial DNA abnormalities in the skeletal muscle of patients with inclusion body myositis. J Neuropathol Exp Neurol 1998; 57:396-403. Mitochondrial DNA depletion may, in addition to mitochondrial DNA deletions, contribute to COX deficiency in muscle fibre segments in sporadic IBM.
61. 61 Oldfors A, Moslemi AR, Fyhr IM, Holme E, Larsson NG, Lindberg C. Mitochondrial DNA deletions in muscle fibers in inclusion body myositis. J Neuropathol Exp Neurol 1995; 54:581-587.
62. 62 Oldfors A, Moslemi A-R, Holme E, Lindberg C. Mitochondrial alterations in sporadic inclusion-body myositis. In: Inclusion body myositis and myopathies. Askanas V, Serratrice G, Engel WK (editors). Cambridge, UK: Cambridge University Press, 1998. pp. 306-317.
63. 63 Moslemi AR, Melberg A, Holme E, Oldfors A. Clonal expansion of mitochondrial DNA with multiple deletions in autosomal dominant progressive external ophthalmoplegia. Ann Neurol 1996; 40:707-713.
64. 64 Moslemi AR, Lindberg C, Oldfors A. Analysis of multiple mitochondrial DNA deletions in inclusion body myositis. Hum Mutat 1997; 10:381-386.
65. 65 Brierley EJ, Johnson MA, Lightowlers RN, James OFW, Turnbull DM. Role of mitochondrial DNA mutations in human aging: implications for the central nervous system and muscle. Ann Neurol 1998; 43:217-223. For the first time it has been shown that mitochondrial DNA deletions that occur in normal elderly individuals may cause COX deficiency in muscle fibre segments similar to what is found in sporadic IBM, although the accumulation of mitochondrial DNA deletions in muscle fibre segments is more frequent in sporadic IBM.
66. 66 Nishino I, Spinazzola A, Hirano M. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science 1999; 283:689-692. This is the first nuclear gene mutation that has been shown to be involved in the formation of multiple mitochondrial DNA deletions in muscle.
67. 67 Lodi R, Taylor DJ, Tabrizi SJ, Hilton-Jones D, Squier MV, Seller A, et al. Normal in vivo skeletal muscle oxidative metabolism in sporadic inclusion body myositis assessed by 31P-magnetic resonance spectroscopy. Brain 1998; 121:2119-2126.
68. 68 Argov Z, Taivassalo T, De Stefano N, Genge A, Karpati G, Arnold DL. Intracellular phosphates in inclusion body myositis: a 31P magnetic resonance spectroscopy study. Muscle Nerve 1998; 21:1523-1525.
69. 69 Lampe J, Kitzler H, Walter MC, Lochmuller H, Reichmann H. Methionine homozygosity at prion gene codon 129 may predispose to sporadic inclusion-body myositis. Lancet 1999; 353:465-466. The results from this study indicate the possibility of an additional genetic factor involved in sporadic IBM.
70. 70 Garlepp MJ, Blechynden L, Tabarias H, Lawon C, van Bockxmeer F, Mastaglia FL. Genetic factors in sporadic inclusion-body myositis. In: Inclusion-body myositis and myopathies. Askanas V, Serratrice G, Engel WK (editors). Cambridge, UK: Cambridge University Press; 1998. pp. 177-188.
71. 71 Garlepp MJ, Tabarias H, Vanbockxmeer FM, Zilko PJ, Laing B, Mastaglia FL. Apolipoprotein E epsilon 4 in inclusion body myositis. Ann Neurol 1995; 38:957-959.
72. 72 Harrington CR, Anderson JR, Chan KK. Apolipoprotein E type epsilon 4 allele frequency is not increased in patients with sporadic inclusion-body myositis. Neurosci Lett 1995; 183:35-38.
73. 73 Askanas V, Engel WK, Mirabella M, Weisgraber KH, Saunders AM, Hoses AD, Mcferrin J. Apolipoprotein E alleles in sporadic inclusion-body myositis and hereditary inclusion-body myopathy [letter]. Ann Neurol 1996; 40:264.
74. 74 Love S, Nicoll JAR, Lowe J, Sherriff F. Apolipoprotein E allele frequencies in sporadic inclusion body myositis. Muscle Nerve 1996; 19:1605-1607.
75. 75 Koffman BM, Sivakumar K, Simonis T, Stroncek D, Dalakas MC. HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies. J Neuroimmunol 1998; 84:139-142. Sporadic IBM but not HIBM is associated with the human leucocyte antigen-DR3 haplotype.
76. 76 Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, JarzabekChorzelska M, Targoff IN, BlaszczykKostanecka M, Jablonska S. Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997; 40:1257-1266.
77. 77 Garlepp MJ, Laing B, Zilko PJ, Ollier W, Mastaglia FL. HLA associations with inclusion body myositis. Clin Exp Immunol 1994; 98:40-45.
78. 78 Rider LG, Gurley RC, Pandey JP, Garcia de la Torre I, Kalovidouris AE, O'Hanlon TP, et al. Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy. Arthritis Rheum 1998; 41:710-719.
79. 79 Sivakumar K, Semino-Mora C, Dalakas MC. An inflammatory, familial, inclusion body myositis with autoimmune features and a phenotype identical to sporadic inclusion body myositis: studies in three families. Brain 1997; 120:653-661.
80. 80 Amato AA, Shebert RT. Inclusion body myositis in twins. Neurology 1998; 51:598-600. This report illustrates that sporadic IBM occasionally can be found in close relatives.
81. 81 Askanas V, Engel WK. New advances in inclusion-body myositis. Curr Opin Rheumatol 1993; 5:732-741.
82. 82 Askanas V, Engel WK. Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: current concepts of diagnosis and pathogenesis. Curr Opin Rheumatol 1998; 10:530-542.
83. 83 Eisenberg I, Thiel C, Levi T, Tiram E Argoz Z, Sadeh M, et al. Fine-structure mapping of the hereditary inclusion body myopathy locus. Genomics 1999; 55:43-48.
84. 84 Ikeuchi T, Asaka T, Saito M, Tanaka H, Higuchi S, Tanaka K, et al. Gene focus for autosoma! recessive distal myopathy with rimmed vacuoles maps to chromosome 9. Ann Neurol 1997; 41:432-437.
85. 85 Åhlberg G, von Tell D, Borg K, Edström L, Anvret M. Genetic linkage of Welander distal myopathy to chromosome 2p13. Ann Neurol 1999 (in press).
86. 86 Haravuori H, Makela-Bengs P, Udd B, Partanen J, Somer H, Peltonen L, et al. Assignment of the tibial muscular dystrophy locus to chromosome 2q31. Am J Hum Genet 1998; 62:620-626.
87. 87 Darin N, Kyllerman M, Wahlström J, Martinsson T, Oldfors A. Autosomal dominant myopathy with congenital joint contractures, ophthalmoplegia, and rimmed vacuoles. Ann Neurol 1998; 44:242-248. This new hereditary IBM shows that rimmed vacuoles occur only in ageing muscle despite of early onset of disease.
88. 88 Martinsson T, Darin N, Kyllerman M, Oldfors A, Hallberg B, Wahlström J. Dominant hereditary inclusion-body myopathy gene (IBM3) maps to chromosome region 17p13.1. Am J Hum Genet 1999; 64:1420-1426. A new HIBM has been linked to a part of chromosome 17, which includes a cluster of myosin heavy chain genes.
89. 89 Goldgaber D, Harris HW, Hla T, Maciag T, Donnelly RJ, Jacobsen JS, et al. Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci USA 1989; 86:7606-7610.
90. 90 Yang CC, Alvarez RB, Engel WK, Askanas V. Increase of nitric oxide synthases and nitrotyrosine in inclusion-body myositis. NeuroReport 1996; 8:153-158.
91. 91 Tews DS, Goebel HH. Cell death and oxidative damage in inflammatory myopathies. Clin Immunol Immunopathol 1998; 87:240-247.
92. 92 Luft R. The development of mitochondrial medicine. Proc Natl Acad Sci USA 1994; 91:8731-8738.
93. 93 Bozner P, Grishko V, LeDoux SP, Wilson GL, Chyan YC, Pappolla MA. The amyloid beta protein induces oxidative damage of mitochondrial DNA. J Neuropathol Exp Neurol 1997; 56:1356-1362.